Changes in Use of Hepatitis C Direct-Acting Antivirals After Access Restrictions Were Eased by State Medicaid Programs
Open Access
- 5 April 2024
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Health Forum
- Vol. 5 (4) , e240302
Abstract
More than 2 million individuals in the US have chronic hepatitis C virus (HCV) infection.1,2 Complications from HCV were responsible for more than 14 000 deaths in the US in 2019, which was more than the next 60 infectious diseases combined before the COVID-19 pandemic.3 Injection drug use, fueled by the ongoing opioid epidemic, was associated with a 400% increase in new HCV infections from 2004 to 2014.4Keywords
This publication has 22 references indexed in Scilit:
- A National Hepatitis C Elimination Program in the United StatesJAMA, 2023
- Difference-in-Differences with multiple time periodsJournal of Econometrics, 2021
- Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part DJAMA Internal Medicine, 2021
- Medicaid Subscription-Based Payment Models and Implications for Access to Hepatitis C MedicationsJAMA Health Forum, 2021
- Association of Medicaid Managed Care Drug Carve Outs With Hepatitis C Virus Prescription UseJAMA Health Forum, 2021
- The Impact of Direct‐Acting Antiviral Therapy on End‐Stage Liver Disease Among Individuals with Chronic Hepatitis C and Substance Use DisordersHepatology, 2021
- Cost-effectiveness of Universal and Targeted Hepatitis C Virus Screening in the United StatesJAMA Network Open, 2020
- Prevalence of Hepatitis C Virus Infection in US States and the District of Columbia, 2013 to 2016JAMA Network Open, 2018
- Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013‐2016Hepatology, 2018
- Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive PopulationJAMA Internal Medicine, 2016